EU/3/16/1643

About

On 28 April 2016, orphan designation (EU/3/16/1643) was granted by the European Commission to Cytori Ltd, United Kingdom, for autologous stromal vascular cell fraction from adipose tissue for the treatment of systemic sclerosis.

The sponsorship was transferred to Clinical Network Services (NL) B.V., Netherlanks, in March 2019.

Key facts

Active substance
Autologous stromal vascular cell fraction from adipose tissue
Disease / condition
Treatment of systemic sclerosis
Date of first decision
28/04/2016
Outcome
Positive
EU designation number
EU/3/16/1643

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Sponsor's contact details

Clinical Network Services (NL) B.V.
De Cuserstraat 93
1081 CN Amsterdam
The Netherlands
Tel. +31 2089 49169
E-mail: cns@clinical.net.au

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;

How useful was this page?

Add your rating